Gemphire's lead drug worsened disease, investigators conclude in ending trial

Capping off a week of bad news, Gemphire Therapeutics revealed Friday morning it will end a Phase 2a trial of its only drug candidate because early results showed it was making patients with non-alcoholic fatty liver disease worse instead of better.